<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572986</url>
  </required_header>
  <id_info>
    <org_study_id>DRL-USG02-P/2015</org_study_id>
    <nct_id>NCT02572986</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% to Elimite™ Cream 5% in the Treatment of Scabies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novum Pharmaceutical Research Services</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scabies is an infestation of the skin by the human itch mite (Sarcoptes scabiei). Diagnosis&#xD;
      of scabies is made based on clinical symptoms, such as nocturnal itching, and appearance and&#xD;
      distribution of the rash. Definitive diagnosis includes the microscopic identification of the&#xD;
      mite, mite eggs, or mite fecal matter in the skin. Topical permethrin is considered the drug&#xD;
      of choice for the treatment of scabies. It is a synthetic pyrethroid that is safe for use in&#xD;
      adults and children 2 months and older.&#xD;
&#xD;
      This study will evaluate the therapeutic equivalence of a generic permethrin cream 5% to&#xD;
      Elimite® in the Treatment of Scabies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with therapeutic cure (parasitological cure plus clinical cure) of scabies</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with no itch persistence</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events assessment</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Scabies</condition>
  <arm_group>
    <arm_group_label>Permethrin cream 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Manufactured by Dr. Reddy's Laboratories, Ltd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elimite™ Cream (permethrin) 5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Manufactured by Prestium Pharma, Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Permethrin</intervention_name>
    <arm_group_label>Elimite™ Cream (permethrin) 5%</arm_group_label>
    <arm_group_label>Permethrin cream 5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent that meets all criteria of current FDA regulations.&#xD;
&#xD;
          2. Male or non-pregnant, non-lactating female at least 2 years of age or older.&#xD;
&#xD;
          3. Diagnosis of active scabies by presence of a burrow and/or typical scabietic lesions&#xD;
             at the classic sites of infestation.&#xD;
&#xD;
          4. Parasitological confirmation of clinical diagnosis with demonstration under light&#xD;
             microscope of mites and/or their products (larvae, eggs or fecal material).&#xD;
&#xD;
          5. Symptom score of 2 or 3 on a 4-point rating scale of 0-3 for nocturnal itching.&#xD;
&#xD;
          6. Women must be either 1 year post-menopausal (no menstrual periods for at least 12&#xD;
             months), surgically sterile, or if they are of child-bearing potential, they must:&#xD;
&#xD;
               -  Have been using systemic birth control, intrauterine device, or used barrier&#xD;
                  methods such as diaphragm plus spermicide or condom plus spermicide consistently,&#xD;
                  at least 14 days before study cream administration.&#xD;
&#xD;
               -  Had a normal menstrual cycle for the month before start of treatment.&#xD;
&#xD;
               -  Have a negative urine pregnancy test result upon entry into the study.&#xD;
&#xD;
               -  Agree to use a medically accepted form of birth control (oral, implant,&#xD;
                  injectable or transdermal contraceptives, intrauterine device, condom plus&#xD;
                  spermicide, diaphragm plus spermicide) or practice abstinence throughout the&#xD;
                  study period.&#xD;
&#xD;
          7. Free from any systemic or dermatologic disorder that, in the opinion of the&#xD;
             Investigator, will interfere with the study results or increase the risk of adverse&#xD;
             events.&#xD;
&#xD;
          8. Ability to apply study product to self or to other person if a child. If patient is a&#xD;
             child, then parent/guardian will apply study product to him/her.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to permethrin cream or any of its components, ragweed or&#xD;
             chrysanthemums, synthetic pyrethroids or pyrethrin.&#xD;
&#xD;
          2. Use of any systemic or topical acaricide 1 month before enrollment.&#xD;
&#xD;
          3. Patients with crusted/Norwegian scabies.&#xD;
&#xD;
          4. Patients with an underlying immunodeficient state (including prolonged treatment with&#xD;
             corticosteroids), immunosuppressive disorders requiring therapy, severe systemic&#xD;
             disease and history of HIV infection.&#xD;
&#xD;
          5. Any condition, medical, psychological, or social, that, in the Investigator's opinion,&#xD;
             would interfere with participation in the study.&#xD;
&#xD;
          6. Women who are pregnant, planning pregnancy or lactating.&#xD;
&#xD;
          7. Family members of employees of the clinic or Investigator.&#xD;
&#xD;
          8. Patients who, in the opinion of the Investigator, would be non-compliant with the&#xD;
             requirements of the study protocol.&#xD;
&#xD;
          9. Patients whose close personal contacts will not or are not willing to comply with&#xD;
             standard of care for Scabies management.&#xD;
&#xD;
         10. Patients less than 2 years of age.&#xD;
&#xD;
         11. Patients or guardians of patients, who are unable or unwilling to give informed&#xD;
             consent or assent respectively.&#xD;
&#xD;
         12. Receipt of any drug as part of a research study within 30 days before screening.&#xD;
&#xD;
         13. History of seizures.&#xD;
&#xD;
         14. Severe cutaneous bacterial or fungal infections requiring therapy (including systemic&#xD;
             and topical antibiotics) or coexisting dermatological disorder that could interfere&#xD;
             with the diagnosis and subsequent monitoring of scabies.&#xD;
&#xD;
         15. Treatment with systemic or topical corticosteroids less than 2 weeks and less than 1&#xD;
             week from enrollment, respectively.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashis Patnaik, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prasanna Ganapathi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shilpi Dhawan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Omni Dermatology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Rise Clinical Research, Inc</name>
      <address>
        <city>Bell Gardens</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Havana Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solutions Through Advanced Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic, Incorporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L &amp; C Professional Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vista Health Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Dx Center for Dermatology</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zain Research, LLC</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Dermatologica</name>
      <address>
        <city>San Salvador</city>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Dermatologica y Cirugia de Piel</name>
      <address>
        <city>Santa Tecla, La Libertad</city>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Dermatologica Dra. Yariela Grajales</name>
      <address>
        <city>Ciudad de Panama</city>
        <state>PanamaCity</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>El Salvador</country>
    <country>Panama</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Permethrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

